European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

DSpace/Manakin Repository

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)
 
Düzel, Emrah; Acosta-Cabronero, Julio; Berron, David; Biessels, Geert Jan; Björkman-Burtscher, Isabella; Bottlaender, Michel; Bowtell, Richard; Buchem, Mark V; Cardenas-Blanco, Arturo; Boumezbeur, Fawzi; Chan, Dennis; Clare, Stuart; Costagli, Mauro; de Rochefort, Ludovic; Fillmer, Ariane; Gowland, Penny; Hansson, Oskar; Hendrikse, Jeroen; Kraff, Oliver; Ladd, Mark E; Ronen, Itamar; Petersen, Esben; Rowe, James B; Siebner, Hartwig; Stoecker, Tony; Straub, Sina; Tosetti, Michela; Uludag, Kamil; Vignaud, Alexandre; Zwanenburg, Jaco; Speck, Oliver
(2019) Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, volume 11, pp. 538 - 549
(Article)
Abstract
Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists. Methods: ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Alzheimer's disease (AD), Magnetic resonance imaging (MRI), Mild cognitive impairment (MCI), Parkinson's disease (PD), Subjective cognitive decline (SCD), Ultrahigh-field MRI, Vascular dementia, Clinical Neurology, Psychiatry and Mental health
DOI: https://doi.org/10.1016/j.dadm.2019.04.010
ISSN: 2352-8729
Publisher: John Wiley & Sons Inc.
Note: Funding Information: The GUFI network was founded at the end of 2013 supported by the German Research Foundation. System reproducibility in human subjects has been compared within the network to validate multicentre brain imaging at 7T, known as the “traveling heads” study [61] . High reproducibility was found across all sites, but differences in intersite versus intrasite reproducibility were identified and assigned to hardware differences. Funding Information: The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). CRMBM 7T program received funding from France Life Imaging (ANR-11-INBS-0006), Investissements d'Avenir (ANR-11-EQPX-0001), Aix-Marseille University Excellence Initiative A*MIDEX (grant ANR-11-IDEX-0001-02). Funding Information: This publication is an outcome of an EU Joint Programme?Neurodegenerative Disease Research (JPND) working group (see www.jpnd.eu). The working group was supported through the German Federal Ministry of Education and Research (BMBF, funding code 01ED1620) under the aegis of JPND. E D?zel receives funding from the Human Brain Project (European Union's Horizon 2020 research and Innovation Program under specific grant agreement No. 720270, SGA1/2, SP3, WP 3.3.1), DFG (SFB 779, A07), DFG (SFB 1315, B06) and the MRC (Project 538374 F69 to E D?zel). The Wellcome Centre for Human Neuroimaging is supported by core funding from the Wellcome (203147/Z/16/Z). JBR is supported by the Wellcome Trust (103838) and Medical Research Council (SUAG/004/91365). The research of Jeroen Hendrikse has received funding from the European Research Council under the European Union's Horizon 2020 Program (H2020)/ERC grant agreement n?637024 (HEARTOFSTROKE) and H2020 grant agreement No 666881, SVDs@target. Jeroen Hendrikse is supported by the Netherlands Organization for Scientific Research (NWO) under grant n?91712322. The research of Jaco Zwanenburg has received funding from the European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreement n?337333 (SmallVesselMRI).The UK7T Network is funded by MRC Partnership Grant MR/N008537/1. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). CRMBM 7T program received funding from France Life Imaging (ANR-11-INBS-0006), Investissements d'Avenir (ANR-11-EQPX-0001), Aix-Marseille University Excellence Initiative A*MIDEX (grant ANR-11-IDEX-0001-02). Mark E. Ladd and Oliver Speck acknowledge support from the German Research Foundation (DFG) for funding of the German Ultrahigh Field Imaging (GUFI) network, grant no. LA 1325/7-1 and SP 632/9-1. Authors' contributions: The authors contributed according to their role in the EUFIND consortium as outlined in the Appendix. Funding Information: Mark E. Ladd and Oliver Speck acknowledge support from the German Research Foundation (DFG) for funding of the German Ultrahigh Field Imaging (GUFI) network, grant no. LA 1325/7-1 and SP 632/9-1 . Funding Information: This publication is an outcome of an EU Joint Programme—Neurodegenerative Disease Research (JPND) working group (see www.jpnd.eu ). The working group was supported through the German Federal Ministry of Education and Research ( BMBF , funding code 01ED1620 ) under the aegis of JPND. E Düzel receives funding from the Human Brain Project (European Union's Horizon 2020 research and Innovation Program under specific grant agreement No. 720270, SGA1/2, SP3, WP 3.3.1), DFG (SFB 779, A07), DFG (SFB 1315, B06) and the MRC (Project 538374 F69 to E Düzel). The Wellcome Centre for Human Neuroimaging is supported by core funding from the Wellcome (203147/Z/16/Z). JBR is supported by the Wellcome Trust (103838) and Medical Research Council (SUAG/004/91365). The research of Jeroen Hendrikse has received funding from the European Research Council under the European Union's Horizon 2020 Program (H2020)/ERC grant agreement n°637024 (HEARTOFSTROKE) and H2020 grant agreement No 666881, SVDs@target. Jeroen Hendrikse is supported by the Netherlands Organization for Scientific Research (NWO) under grant n° 91712322 . The research of Jaco Zwanenburg has received funding from the European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreement n°337333 (SmallVesselMRI).The UK7T Network is funded by MRC Partnership Grant MR/N008537/1. Funding Information: Established in 2015 and funded by the UK Medical Research Council, this network aims to develop a platform for multicentre trials at 7T, enable multivendor studies and produce “work-horse” protocols. In a similar way to GUFI, the UK7T network has carried out a “traveling head” study with 10 participants across 5 sites, using a range of harmonized protocols including structural and functional measures. Initial data show that, as well as matching protocol parameters as much as possible, it is essential to standardize the various calibration steps (transmit power, B0 shim), to improve uniformity [63] . At present, QA procedures and a common phantom are also being disseminated among the UK7T partners. Publisher Copyright: © 2018 The Authors
(Peer reviewed)